Clinical trials with psychopharmacologic drugs - a regulatory point of view

被引：0

|

作者：

Broich, K ^{[1
]}

机构：

[1] Bundesinst Arzneimittel & Med Prod, Bonn, Germany

来源：

PHARMACOPSYCHIATRY | 2005年 / 38卷 / 05期

关键词：

D O I：

暂无

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

引用

收藏

页码：233 / 233

页数：1

相关论文

共 50 条

[21] Probiotic foods and drugs: Impact of US regulatory status on design of clinical trials
Hibberd, Patricia L.
Davidson, Lisa
CLINICAL INFECTIOUS DISEASES, 2008, 46 : S137 - S140
[22] PSYCHOPHARMACOLOGIC DRUGS AND FISH BEHAVIOR
ATZ, JW
ANATOMICAL RECORD, 1959, 134 (03): : 529 - 530
[23] Drugs in clinical trials
不详
ALZHEIMERS REPORTS, 1999, 2 (03): : 181 - 182
[24] Cardiac Safety - a Regulatory view point
Prasad, K.
TOXICOLOGY LETTERS, 2018, 295 : S49 - S49
[25] GFR Decline as an End Point for Clinical Trials in CKD: A View From Europe
Mol, Peter G. M.
Maciulaitis, Romaldas
Vetter, Thorsten
AMERICAN JOURNAL OF KIDNEY DISEASES, 2014, 64 (06) : 838 - 840
[26] POINT OF VIEW OF JURIST ON COMPARATIVE TRIALS
ARPAILLANGE, P
GASTON, JL
BIOMEDICINE, 1978, 28 : 57 - 59
[27] RISK-BENEFIT ASSESSMENT OF NEW ANTIINFECTIVE DRUGS - THE POINT-OF-VIEW OF THE REGULATORY AUTHORITY
CHRIST, W
ESCH, B
INFECTION, 1991, 19 : S65 - S71
[28] EFFECTS OF PSYCHOPHARMACOLOGIC DRUGS ON NOISE SENSATION
KOHNEN, R
KRUGER, HP
ZEITSCHRIFT FUR EXPERIMENTELLE UND ANGEWANDTE PSYCHOLOGIE, 1980, 27 (03): : 428 - 444
[29] Regulatory TEVAR clinical trials
Garcia-Toca, Manuel
Eskandari, Mark K.
JOURNAL OF VASCULAR SURGERY, 2010, 52 : 22S - 25S
[30] Biostatistics and clinical trials: a view
Lee, YJ
JOURNAL OF STATISTICAL PLANNING AND INFERENCE, 1999, 78 (1-2) : 349 - 367

← 1 2 3 4 5 →